Trial Outcomes & Findings for Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL (NCT NCT02362997)

Last Updated: 2026-02-12

Results Overview

Proportion of patients alive and disease-free 18 months from autologous stem cell transplantation (ASCT). Progression criteria are per Lugano 2014 criteria. All patients receiving any amount of protocol treatment. Patients who have progressed or lost to follow-up prior to 18 months are counted as failures; only patients followed and progression-free for at least 18 months are counted as successes.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

82 participants

Primary outcome timeframe

18 Months

Results posted on

2026-02-12

Participant Flow

Participant milestones

Participant milestones
Measure	Diffuse Large B Cell Lymphoma Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Peripheral T Cell Lymphoma Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody
Overall Study STARTED	31	30	21
Overall Study COMPLETED	31	30	21
Overall Study NOT COMPLETED	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Diffuse Large B Cell Lymphoma n=31 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma n=30 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Peripheral T Cell Lymphoma n=21 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Total n=82 Participants Total of all reporting groups
Age, Categorical >=65 years	8 Participants n=47 Participants	1 Participants n=55 Participants	6 Participants n=102 Participants	15 Participants n=1267 Participants
Age, Continuous	57 years n=47 Participants	34 years n=55 Participants	58 years n=102 Participants	50 years n=1267 Participants
Sex: Female, Male Female	9 Participants n=47 Participants	14 Participants n=55 Participants	9 Participants n=102 Participants	32 Participants n=1267 Participants
Sex: Female, Male Male	22 Participants n=47 Participants	16 Participants n=55 Participants	12 Participants n=102 Participants	50 Participants n=1267 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=47 Participants	0 Participants n=55 Participants	0 Participants n=102 Participants	1 Participants n=1267 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	24 Participants n=47 Participants	18 Participants n=55 Participants	13 Participants n=102 Participants	55 Participants n=1267 Participants
Race (NIH/OMB) More than one race	1 Participants n=47 Participants	1 Participants n=55 Participants	0 Participants n=102 Participants	2 Participants n=1267 Participants
Race (NIH/OMB) Unknown or Not Reported	4 Participants n=47 Participants	12 Participants n=55 Participants	8 Participants n=102 Participants	24 Participants n=1267 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	6 Participants n=47 Participants	12 Participants n=55 Participants	8 Participants n=102 Participants	26 Participants n=1267 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=47 Participants	0 Participants n=55 Participants	0 Participants n=102 Participants	0 Participants n=1267 Participants
Race (NIH/OMB) Asian	0 Participants n=47 Participants	0 Participants n=55 Participants	1 Participants n=102 Participants	1 Participants n=1267 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=47 Participants	0 Participants n=55 Participants	0 Participants n=102 Participants	0 Participants n=1267 Participants
Race (NIH/OMB) Black or African American	1 Participants n=47 Participants	0 Participants n=55 Participants	2 Participants n=102 Participants	3 Participants n=1267 Participants
Race (NIH/OMB) White	25 Participants n=47 Participants	17 Participants n=55 Participants	10 Participants n=102 Participants	52 Participants n=1267 Participants
Region of Enrollment United States	31 participants n=47 Participants	30 participants n=55 Participants	21 participants n=102 Participants	82 participants n=1267 Participants
Age, Categorical Between 18 and 65 years	23 Participants n=47 Participants	29 Participants n=55 Participants	15 Participants n=102 Participants	67 Participants n=1267 Participants
ECOG Performance Score 00- Fully Active	10 Participants n=47 Participants	14 Participants n=55 Participants	4 Participants n=102 Participants	28 Participants n=1267 Participants
ECOG Performance Score 01- Restricted	20 Participants n=47 Participants	16 Participants n=55 Participants	16 Participants n=102 Participants	52 Participants n=1267 Participants
ECOG Performance Score 02- Ambulatory and Capable of Self Care	1 Participants n=47 Participants	0 Participants n=55 Participants	1 Participants n=102 Participants	2 Participants n=1267 Participants
Age, Categorical <=18 years	0 Participants n=47 Participants	0 Participants n=55 Participants	0 Participants n=102 Participants	0 Participants n=1267 Participants

PRIMARY outcome

Timeframe: 18 Months

Outcome measures

Outcome measures
Measure	Diffuse Large B Cell Lymphoma n=31 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma n=30 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Peripheral T Cell Lymphoma n=21 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma - PET-NCR Classical Hodgkin Lymphoma patients who were not PET-CR before transplantation	Peripheral T Cell - PET-CR Peripheral T Cell patients who were PET-CR before transplantation	Peripheral T Cell - PET-NCR Peripheral T Cell patients who were not PET-CR before transplantation
Progression-free Survival After ASCT	0.58 proportion of participants Interval 0.42 to 0.73	0.77 proportion of participants Interval 0.61 to 0.89	0.62 proportion of participants Interval 0.42 to 0.79	—	—	—

SECONDARY outcome

Timeframe: 18 Months

Survival probability of patients alive 18 months from ASCT, time-to-event

Outcome measures

Outcome measures
Measure	Diffuse Large B Cell Lymphoma n=31 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma n=30 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Peripheral T Cell Lymphoma n=21 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma - PET-NCR Classical Hodgkin Lymphoma patients who were not PET-CR before transplantation	Peripheral T Cell - PET-CR Peripheral T Cell patients who were PET-CR before transplantation	Peripheral T Cell - PET-NCR Peripheral T Cell patients who were not PET-CR before transplantation
Overall Survival	0.93 survival probability Interval 0.85 to 1.0	1.0 survival probability Interval 1.0 to 1.0	0.94 survival probability Interval 0.86 to 1.0	—	—	—

SECONDARY outcome

Timeframe: 18 Months

Population: Patients who have been followed for at least 18 months or have relapsed prior to 18 months post ASCT

Number of patients who relapse within 18 months from autologous stem cell transplantation.

Outcome measures

Outcome measures
Measure	Diffuse Large B Cell Lymphoma n=25 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma n=28 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Peripheral T Cell Lymphoma n=16 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma - PET-NCR Classical Hodgkin Lymphoma patients who were not PET-CR before transplantation	Peripheral T Cell - PET-CR Peripheral T Cell patients who were PET-CR before transplantation	Peripheral T Cell - PET-NCR Peripheral T Cell patients who were not PET-CR before transplantation
Relapse	11 Participants	4 Participants	4 Participants	—	—	—

SECONDARY outcome

Timeframe: 6 months

Number of patients who experienced at least a grade 2 toxicity with "definite," "probable," or "possible" attribute to study treatment, according to the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Outcome measures

Outcome measures
Measure	Diffuse Large B Cell Lymphoma n=31 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma n=30 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Peripheral T Cell Lymphoma n=21 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma - PET-NCR Classical Hodgkin Lymphoma patients who were not PET-CR before transplantation	Peripheral T Cell - PET-CR Peripheral T Cell patients who were PET-CR before transplantation	Peripheral T Cell - PET-NCR Peripheral T Cell patients who were not PET-CR before transplantation
Safety and Tolerability Assessed by CTCAE v4 Grade 2 and Above Toxicity Related to Study Treatment	21 Participants	15 Participants	12 Participants	—	—	—

SECONDARY outcome

Timeframe: 18 months

In patients with measurable disease after ASCT, rate of objective response after treatment. Response was assessed using the Lugano 2014 criteria.

Outcome measures

Outcome measures
Measure	Diffuse Large B Cell Lymphoma n=31 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma n=30 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Peripheral T Cell Lymphoma n=21 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma - PET-NCR Classical Hodgkin Lymphoma patients who were not PET-CR before transplantation	Peripheral T Cell - PET-CR Peripheral T Cell patients who were PET-CR before transplantation	Peripheral T Cell - PET-NCR Peripheral T Cell patients who were not PET-CR before transplantation
Response Rate to Pembrolizumab	0.74 proportion of participants Interval 0.58 to 0.86	0.90 proportion of participants Interval 0.76 to 0.97	0.86 proportion of participants Interval 0.67 to 0.96	—	—	—

SECONDARY outcome

Timeframe: 18 months

Progression-free survival probability of patients who are alive and without progression 18 months from ASCT, time-to-event

Outcome measures

Outcome measures
Measure	Diffuse Large B Cell Lymphoma n=31 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma n=30 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Peripheral T Cell Lymphoma n=21 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma - PET-NCR Classical Hodgkin Lymphoma patients who were not PET-CR before transplantation	Peripheral T Cell - PET-CR Peripheral T Cell patients who were PET-CR before transplantation	Peripheral T Cell - PET-NCR Peripheral T Cell patients who were not PET-CR before transplantation
Progression-free Survival	0.74 progression-free survival probability Interval 0.62 to 0.9	0.87 progression-free survival probability Interval 0.77 to 0.97	0.84 progression-free survival probability Interval 0.7 to 0.99	—	—	—

OTHER_PRE_SPECIFIED outcome

Timeframe: 18 months

Survival probability of patients alive 18 months from ASCT stratified by PET status before transplantation, time-to-event. Patients categorized by complete metabolic response (complete response by PET scan, assessed using the Lugano 2014 criteria), partial response (assessed using Lugano 2014 criteria) prior to transplantation.

Outcome measures

Outcome measures
Measure	Diffuse Large B Cell Lymphoma n=20 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma n=11 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Peripheral T Cell Lymphoma n=23 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma - PET-NCR n=7 Participants Classical Hodgkin Lymphoma patients who were not PET-CR before transplantation	Peripheral T Cell - PET-CR n=19 Participants Peripheral T Cell patients who were PET-CR before transplantation	Peripheral T Cell - PET-NCR n=2 Participants Peripheral T Cell patients who were not PET-CR before transplantation
Overall Survival After ASCT by PET Status	0.94 survival probability Interval 0.85 to 1.0	0.91 survival probability Interval 0.78 to 1.0	1.0 survival probability Interval 1.0 to 1.0	1.0 survival probability Interval 1.0 to 1.0	0.94 survival probability Interval 0.84 to 1.0	1.0 survival probability Interval 1.0 to 1.0

OTHER_PRE_SPECIFIED outcome

Timeframe: 18 months

Progression-free survival probability of patients alive and disease-free 18 months from ASCT stratified by PET status before transplantation, time-to-event

Outcome measures

Outcome measures
Measure	Diffuse Large B Cell Lymphoma n=20 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma n=11 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Peripheral T Cell Lymphoma n=23 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma - PET-NCR n=7 Participants Classical Hodgkin Lymphoma patients who were not PET-CR before transplantation	Peripheral T Cell - PET-CR n=19 Participants Peripheral T Cell patients who were PET-CR before transplantation	Peripheral T Cell - PET-NCR n=2 Participants Peripheral T Cell patients who were not PET-CR before transplantation
Progression-free Survival After ASCT by PET Status	0.87 progression-free survival probability Interval 0.74 to 1.0	0.54 progression-free survival probability Interval 0.35 to 0.86	0.82 progression-free survival probability Interval 0.7 to 0.97	1.0 progression-free survival probability Interval 1.0 to 1.0	0.82 progression-free survival probability Interval 0.67 to 0.99	1.0 progression-free survival probability Interval 1.0 to 1.0

OTHER_PRE_SPECIFIED outcome

Timeframe: 18 months

Number of patients who complete the planned treatment

Outcome measures

Outcome measures
Measure	Diffuse Large B Cell Lymphoma n=31 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma n=30 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Peripheral T Cell Lymphoma n=21 Participants Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma - PET-NCR Classical Hodgkin Lymphoma patients who were not PET-CR before transplantation	Peripheral T Cell - PET-CR Peripheral T Cell patients who were PET-CR before transplantation	Peripheral T Cell - PET-NCR Peripheral T Cell patients who were not PET-CR before transplantation
Completion Rate	18 Participants	23 Participants	14 Participants	—	—	—

OTHER_PRE_SPECIFIED outcome

Timeframe: 18 months

Level of MRD detected by PCR (if feasible) before and after pembrolizumab

Outcome measures

Outcome data not reported

Adverse Events

Diffuse Large B Cell Lymphoma

Serious events: 8 serious events

Other events: 29 other events

Deaths: 2 deaths

Classical Hodgkin Lymphoma

Serious events: 3 serious events

Other events: 30 other events

Deaths: 0 deaths

Peripheral T Cell Lymphoma

Serious events: 1 serious events

Other events: 21 other events

Deaths: 3 deaths

Serious adverse events

Serious adverse events
Measure	Diffuse Large B Cell Lymphoma n=31 participants at risk Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Classical Hodgkin Lymphoma n=30 participants at risk Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody	Peripheral T Cell Lymphoma n=21 participants at risk Pembrolizumab 200mg IV every 3 weeks up to 8 cycles Pembrolizumab: Anti-PD-1 monoclonal antibody
Investigations Neutrophil count decreased	19.4% 6/31 • Number of events 6 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	10.0% 3/30 • Number of events 4 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	0.00% 0/21 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT
Investigations Platelet count decreased	6.5% 2/31 • Number of events 2 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	0.00% 0/30 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	0.00% 0/21 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT
Investigations White blood cell decreased	3.2% 1/31 • Number of events 1 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	3.3% 1/30 • Number of events 1 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	0.00% 0/21 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT
Gastrointestinal disorders Enterocolitis	0.00% 0/31 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	3.3% 1/30 • Number of events 1 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	0.00% 0/21 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/31 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	3.3% 1/30 • Number of events 1 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	0.00% 0/21 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT
Musculoskeletal and connective tissue disorders Musculoskeletal and connective tissue disorder - Other, specify	3.2% 1/31 • Number of events 1 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	0.00% 0/30 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	0.00% 0/21 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify	3.2% 1/31 • Number of events 1 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	0.00% 0/30 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	0.00% 0/21 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/31 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	0.00% 0/30 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	4.8% 1/21 • Number of events 1 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT
Respiratory, thoracic and mediastinal disorders Respiratory, thoracic and mediastinal disorders - Other, specify	3.2% 1/31 • Number of events 1 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	0.00% 0/30 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	0.00% 0/21 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT
Nervous system disorders Syncope	3.2% 1/31 • Number of events 1 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	0.00% 0/30 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT	0.00% 0/21 • Safety assessments will be performed on day 1 of each of up to 8 treatment cycles (28-day cycle) followed by assessments every 3 months until up to 18-months post-ASCT

Other adverse events

Additional Information

Philippe Armand, MD, PhD

Dana-Farber Cancer Institute

Phone: 617-632-2305

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place